Anti-obesity drugs: Past, present and future

DMM Disease Models and Mechanisms

Volumn 5, Issue 5, 2012, Pages 621-626

  Rodgers, R John ^a   Tschöp, Matthias H ^b   Wilding, John P H ^c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,4 BENZODIOXAN 2 CARBOXYLIC ACID; ADP 359; AMFEBUTAMONE PLUS NALTREXONE; AMFEPRAMONE; AMITIFADINE; AMPHETAMINE DERIVATIVE; AMYLIN DERIVATIVE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; ATHX 105; BELVIQ; BVT 74316; CETILISTAT; DEXFENFLURAMINE; FENFLURAMINE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; LORCASERIN; METHAMPHETAMINE; NALOXONE; OBINEPITIDE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PRX 07034; QSYMIA; REMOGLIFLOZIN ETABONATE; RIMONABANT; SIBUTRAMINE; TESOFENSINE; TETRAHYDROLIPSTATIN; TKS 1225; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELNEPERIT;

ABDOMINAL PAIN; ANXIETY; BIRTH DEFECT; BLOATING; CALORIC INTAKE; CARDIOTOXICITY; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSPEPSIA; ENERGY EXPENDITURE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GENETIC SCREENING; HUMAN; LOW DRUG DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OBESITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; SIGNAL TRANSDUCTION; SUICIDE; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; DRUG THERAPY, COMBINATION; HUMANS; OBESITY;

EID: 84865504290     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.009621     Document Type: Note

References (71)

1. Adan, R. A. H., Vanderschuren, L. J. M. J. and la Fleur, S. E. (2008). Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol. Sci. 29, 208-217.
2. Aronne, L. J., Halseth, A. E., Burns, C. M., Miller, S. and Shen, L. Z. (2010). Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity 18, 1739-1746.
3. Astrup, A., Rossner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Madsen, J., Rasmussen, M. F. and Lean, M. E. J. (2009). Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374, 1606-1616.
4. Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M, Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., Rossner, S. et al. (2011). Safety, tolerability and sustained weight loss over 2 years with once daily human GLP-1 analog, liraglutide. Int. J. Obesity 36, 890.
5. Bermudez-Silva, F. J., Viveros, M. P., McPartland, J. M. and Rodriguez de Fonseca, F. (2010). The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol. Biochem. Behav. 95, 375-382.
6. Borgstrom, B. (1988). Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim. Biophys. Acta 962, 308-316.
7. Bray, G. A. and Greenway, F. L. (2007). Pharmacological treatment of the overweight patient. Pharmacol. Rev. 59, 151-184. (Pubitemid 46855438)
8. Broom, I., Wilding, J., Scott, P. and Myers, N. (2002). Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study. Int. J. Clin. Pract. 56, 494-499.
9. Chen, W., Tang, H., Liu, H., Long, L., Gong, Z, Zheng, J., Chi, M., Xie, Y., Zheng, Z., Li, S. et al. (2010). Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models. Eur. J. Pharmacol. 637, 178-185.
10. Cluny, N. L., Chambers, A. P., Vemuri, V. K., Wood, J. T., Eller, L. K., Freni, C., Reimer, R. A., Makriyannis, A. and Sharkey, K. A. (2011). The neutral cannabinoid CB1 receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol. Biochem. Behav. 97, 537-543.
11. Colman, E. (2005). Anorectics on trial: a half-century of federal regulation of prescription appetite suppressants. Ann. Int. Med. 143, 380-385.
12. Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D. and Schaff, H. V. (1997). Valvular heart disease associated with fenfluramine-phentermine. N. Eng. J. Med. 337, 581-588. (Pubitemid 27360757)
13. Cooke, D. and Bloom, S. (2006). The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat. Rev. Drug Discov. 5, 919-931. (Pubitemid 44660605)
14. Daniels, J. (2006a). Obesity: America's epidemic. Am. J. Nurs. 106, 40-49.
15. Daniels, S. R. (2006b). The consequences of childhood overweight and obesity. Future Child 16, 47-67.
16. Dansinger, M. L., Gleason, J. A., Griffith, J. L., Selker, H. P. and Schaefer, E. J. (2005). Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease reduction: a randomised trial. JAMA 293, 43-53. (Pubitemid 40066698)
17. Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J, Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N. et al. (2009). A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 5, 749-757.
18. Despres, J. P., Golay, A. and Sjostrom, L. (2005). Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Eng. J. Med. 353, 2121-2134. (Pubitemid 41653104)
19. Field, B. C. T., Chaudhri, O. B. and Bloom, S. R. (2009). Obesity treatment: novel peripheral targets. Br. J. Clin. Pharmacol. 68, 830-843.
20. Flegal, K. M., Graubard, B. I., Williamson, D. F. and Gail, M. H. (2007). Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 298, 2028-2037. (Pubitemid 350074800)
21. Fontaine, K. R., Redden, D. T., Wang, C., Westfall, A. J. and Allison, D. B. (2003). Years of life lost due to obesity. JAMA 298, 187-193. (Pubitemid 36068706)
22. Freedman, D. S., Khan, L. K., Dietz, W. H., Srinivasan, S. R. and Berenson, G. S. (2001). Relationship of childhood obesity to coronary heart disease risk factors in adulthood: the Bogalusa Heart Study. Pediatrics 108, 712-718. (Pubitemid 32786603)
23. Greenway, F. L., Whitehouse, M. J., Guttadauria, M., Anderson, J. W., Atkinson, R. L., Fujioka, K., Gadde, K. M., Gupta, A. K., O'Neil, P., Schumacher, D. et al. (2009). Rational design of a combination medication for the treatment of obesity. Obesity 17, 30-39. (Pubitemid 50324544)
24. Halford, J. C. G., Boyland, E. J., Blundell, J. E., Kirkham, T. C. and Harrold, J. A. (2010). Pharmacological management of appetite expression in obesity. Nat. Rev. Endocrinol. 6, 255-269.
25. Hanssen, K. B., Knop, F. K., Holst, J. J. and Vilsboll, T. (2009). Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Int. J. Clin. Pract. 63, 1154-1160.
26. Haslam, D. W. and James, W. P. T. (2005). Obesity. Lancet 366, 1197-1209. (Pubitemid 41393598)
27. Heal, D. J., Gosden, J. and Smith, S. L. (2009). Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br. J. Clin. Pharmacol. 68, 861-874.
28. James, W. P. T., Caterson, I. D., Couthino, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pederson, C., Sharma, A. M., Shepherd, G. M., Rode, R. A. et al. (2010). Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Eng. J. Med. 363, 905-917.
29. Kennett, G. A. and Clifton, P. G. (2010). New approaches to the pharmacological treatment of obesity: Can they break through the efficacy barrier? Pharmacol. Biochem. Behav. 97, 63-83.
30. Kirkham, T. C. (2009). Cannabinoids and appetite: food craving and food pleasure. Int. Rev. Psychiat. 21, 163-171.
31. Kopelman, P. G. (2000). Obesity as a medical problem. Nature 404, 635-643.
32. Kral, J. G. and Naslund, E. (2007). Surgical treatment of obesity. Nature Clin Pract: Endocrinol. Metab. 3, 574-583. (Pubitemid 47094562)
33. Kreymann, B., Williams, G., Ghatei, M. A. and Bloom S. R. (1987). Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2, 1300-1304. (Pubitemid 17156636)
34. Kunos, G., Osei-Hyiaman, D., Batkai, S., Sharkey, K. A. and Makriyannis, A. (2008). Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol. Sci. 30, 1-7.
35. Lazary, J., Juhasz, G, Hunyady, L. and Bagdy, G. (2011). Personalized medicine can pave the way for the safe use of CB1 receptor antagonists. Trends Pharmacol. Sci. 32, 270-280.
36. LeBlanc, E. S., O'Connor, E., Wtitlock, P. D., Patnode, C. D. and Kapka, T. (2011). Effectiveness of primary care -relevant treatments for obesity in adults: a systematic evidence review for the U. S. Preventive Services Task Force. Ann. Int. Med. 155, 434-447.
37. Li, Z., Maglione, M., Tu, W., Mojica, D., Arterburn, D., Shugaman, L. R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P. G. et al. (2005). Meta-analysis: pharmacologic treatment of obesity. Ann. Intern. Med. 142, 532-546.
38. Lockie, S. H., Czyzyk, T. A., Chaudhary, N., Perez-Tilve, D., Woods, S. C., Oldfield, B. J., Statnick, M. A. and Tschöp, M. H. (2011). CNS opioid signaling separates cannabinoid receptor 1-mediated effects on body weight and mood-related behavior in mice. Endocrinol. 152, 3661-3667.
39. Luque, C. A. and Rey, J. A. (2002). The discovery and status of sibutramine as an antiobesity drug. Eur. J. Pharmacol. 440, 119-128. (Pubitemid 34458019)
40. McNeely, W. and Goa, K. L. (1998). Sibutramine. A review of its contribution to the management of obesity. Drugs 56, 1093-1124. (Pubitemid 29010230)
41. McPherson, K., Marsh, T. and Brown, M. (2007). Tackling obesities: future choices. Modelling future trends in obesity and their impact on health. 2nd Edition. Government Office for Science: London.
42. Melnikova, I. and Wages, D. (2006). Anti-obesity therapies. Nat. Rev. Drug Discov. 5, 369-370. (Pubitemid 43904927)
43. National Audit Office (2001). Tackling obesity in England. Report by the Comptroller and Auditor General. The Stationery Office: London.
44. Orio, L., Crespo, I., Lopez-Moreno, J. A., Reyes-Cabello, C., Rodriguez de Fonseca, F. and Gomez de Heras, R. (2011). Additive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition. Pharmacol. Biochem. Behav. 98, 220-226.
45. Padwal, R. (2009). Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Curr. Opin. Invest. Drugs 10, 1117-1125.
46. Pertwee, R. G. (2006). The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obesity 30, S13-S18.
47. Pi-Sunyer, F., Aronne, L. J., Heshmati, H. M., Devin, J. and Rosenstock, J. (2006). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk in overweight or obese patients - RIO-North America: a randomised controlled trial. JAMA 295, 761-775. (Pubitemid 43244304)
48. Plieth, J. (2008). Obesity: what next after the CB1 antagonists' failure. Scrip 2008, 44-47.
49. Randall, P. A., Vemuri, V. K., Segovia, K. N., Torres, E. F., Hosmer, S., Nunes, E. J., Santerre, J. L., Makriyannis, A. and Salamone, J. D. (2010). The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol. Biochem. Behav. 97, 179-184.
50. Ravussin, E., Smith, S. R., Mitchell, J. A., Shringarpure, R., Shan, K., Maier, H., Koda, J. E. and Weyer, C. (2009). Enhanced weight loss with pramlintide/metreleptin: an integrated neurohumoral approach to obesity pharmacotherapy. Obesity 17, 1736-1743.
51. Rodgers, R. J., Holch, P. and Tallett, A. J. (2010). Behavioural satiety sequence (BSS): Separating wheat from chaff in the behavioural pharmacology of appetite. Pharmacol. Biochem. Behav. 97, 3-14.
52. Roth, J. D., Trevaskis, J. L., Wilson, J., Lei, C., Athanacio, J., Mack, C., Kesty, N. C., Coffey, T., Weyer, C. and Parkes, D. G. (2008). Antiobesity effects of the beta-cell hormone amylin in combination with phenteramine or sibutramine in diety-induced obese rats. Int. J. Obesity 32, 1201-1210.
53. Roth, J. D., Trevaskis, J. L., Turek, V. F. and Parkes, D. G. (2010). 'Weighing in' on synergy: preclinical research on neurohumoral anti-obesity combinations. Brain Res. 1350, 86-94.
54. Salter, J. M. (1960). Metabolic effects of glucagon in the Wistar rat. Am. J. Clin. Nutr. 8, 535-539.
55. Sargent, B. J. and Moore, N. A. (2009). New central targets for the treatment of obesity. Br. J. Clin. Pharmacol. 68, 852-860.
56. Scheen, A. J., Finer, N., Hollander, P., Jensen, M. D. and Van Gaal, L. F. (2006). Efficacy and tolerability of rimonabant in oiverweight or obese patients with Type 2 diabetes: a randomised controlled study. Lancet 368, 1660-1672. (Pubitemid 46048528)
57. Sjostrom, L., Narbro, K., Sjostrom, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B. et al. (2007). Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Eng. J. Med. 357, 741-752. (Pubitemid 47295641)
58. Tallett, A. J., Blundell, J. E. and Rodgers, R. J. (2008). Endogenous opioids and cannabinoids: system interactions in the regulation of appetite, grooming and scratching. Physiol. Behav. 94, 422-431. (Pubitemid 351680293)
59. Torgerson, J. S., Hauptman, J., Boldrin, M. N. and Sjostrom, L. (2004). Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomised study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27, 155-161. (Pubitemid 38196725)
60. Trevaskis, J. L., Coffey, T., Cole, R., Lei, C., Wittmer, C., Walsh, B., Weyer, C., Koda, J., Baron, A. D., Parkes, D. G. et al. (2008). Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology 149, 5679-5687.
61. Turton, M. D., O'Shea, D., Gunn, I., Edwards, C. M. B., Meeran, K., Heath, M., Lambert, P. D., Wilding, J. P. H., Smith, D. M., Ghatei, M. A. et al. (2006). A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69-72.
62. Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O. and Rossner, S. (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from RIO-Europe study. Lancet 365, 1389-1397. (Pubitemid 40523733)
63. Vemuri, V. K., Janero, D. R. and Makriyannis, A. (2008). Therapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol. Behav. 93, 671-686. (Pubitemid 351410420)
64. Vickers, S. P. and Cheetham, S. C. (2007). Preclinical developments in antiobesity drugs. In Appetite and Body Weight (ed. T. C. Kirkham and S. J. Cooper), pp. 323-336. London: Academic Press.
65. Vickers, S. P., Jackson, H. C. and Cheetham, S. C. (2011). The utility of animal models to evaluate novel anti-obesity agents. Br. J. Pharmacol. 164, 1248-1262.
66. Ward, S. J., Lefever, T. W., Jackson, C., Tallarida, R. J. and Walker, E. A. (2008). Effects of a cannabinoid1 receptor antagonist and serotonin2C receptor agonist alone and in combination on motivation for palatable food: a dose addition analysis study in mice. J. Pharmacol. Exp. Ther. 325, 567-576. (Pubitemid 351574781)
67. Weintraub, M., Sundaresan, P. R., Madan, M., Schuster, B., Balder, A., Lasagna, L. and Cox, C. (1992). Long-term weight control study, 1 (weeks 0-34) - the enhancement of behavior-modification, caloric restriction, and exercise by fenfluramine plus phentermine. Clin. Pharmacol. Ther. 51, 586-594.
68. Wilding, J. (2007). Clinical investigations of antiobesity drugs. In Appetite and Body Weight (ed. T. C. Kirkham and S. J. Cooper), pp. 337-355. London: Academic Press.
69. Wilding, J. P. H. and Hardy, K. (2011). New drugs for diabetes: glucagon-like peptide 1 analogues. BMJ 342, 343-346.
70. Wing, R. R., Tate, D. F., Gorin, A. A., Raynor, H. A. and Fava, J. L. (2006). A selfregulation program for maintenance of weight loss. N. Eng. J. Med. 355, 1563-1571. (Pubitemid 44547807)
71. Woods, S. C., Lutz, T. A., Geary, N. and Langhans, W. (2006). Pancreatic signals controlling food intake: insulin, glucagon and amylin. Philos. Trans. R. Soc. Lond. B Biol. Sci. 361, 1219-1235. (Pubitemid 44882937)